Press Release
Details
AVROBIO, Inc. Appoints Phillip B. Donenberg to its Board of Directors
AVROBIO, Inc. Appoints Phillip B. Donenberg to its Board of Directors
“Phil brings a strong track record of success and leadership experience in the field of gene therapy that is directly relevant to our business and stage of growth at AVROBIO,” said
Mr. Donenberg has held leadership roles overseeing strategic transactions, financing management and accounting operations, controls and reporting processes for growing companies. Most recently, he has been appointed as Chief Financial Officer and Senior Vice President of
“I am excited to become part of the
About
Cautionary Note Regarding Forward-Looking Statements
Various express or implied statements in this release concerning AVROBIO’s future expectations, plans and prospects, including without limitation, its expectations regarding the contributions of any member of its board of directors, including such member’s ability to affect AVROBIO’s development or growth plans, and statements regarding the development and the continued progress of AVROBIO’s programs, and the therapeutic potential of its product candidates, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any forward-looking statements in this press release are based on management’s current expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIO’s product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any of AVROBIO’s ongoing or planned clinical trials, and the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving AVROBIO’s product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIO’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in the final prospectus related to AVROBIO’s initial public offering filed with the
Investor Contacts:Katina Dorton AVROBIO, Inc. 617-914-8413 katina.dorton@avrobio.comChristopher F. Brinzey Westwicke Partners 339-970-2843 chris.brinzey@westwicke.com Media Contact:Kathryn Morris The Yates Network 914-204-6412 kathryn@theyatesnetwork.com
Source: AVROBIO, Inc.